Month: March 2026

Gold Stevie Award winner for Best Use of AI Integration in Contact Centers NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, has won a Gold Stevie Award in the transforming contact centers with intelligent agent assistance category in the 20th annual Stevie Awards for Sales & Customer Service. The Stevie Awards for Sales & Customer Service are the world’s top honors for customer service, contact center, business development and sales professionals. The Stevie Awards organizes nine of the world’s leading business awards programs, also including the prestigious American Business Awards® and International Business Awards®. More than 2,100 nominations from organizations of all sizes and in virtually every industry, in 41 nations and territories, were considered in this year’s competition....

Next phase of RELI Exchange is designed to expand recruiting capacity, improve execution and build on the platform’s strong operating momentum LAKEWOOD, NJ, March 25, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (“we,” “us,” “our,” the “Company” or “Reliance”) today announced the launch of RELI Exchange 2.0, the next phase of its InsurTech platform for independent insurance agencies, designed to expand recruiting capacity, improve execution and position the platform for faster, more efficient growth. In February 2026, Reliance reported that health insurance policies written through RELI Exchange during the 2025 open enrollment period increased 72% year over year, Personal Lines Property and Casualty written premium increased 36% year over year, and the broker network expanded from approximately 65 to approximately...

CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”) today announced that it has completed its previously announced exchange offer to each holder of its Series C Non-Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), to exchange such Series C Preferred Stock for shares of Enzon’s common stock, $0.01 par value per share (the “Common Stock”). The offer and the withdrawal rights expired at 5:00 p.m., Eastern Time, on March 24, 2026. The offer was made pursuant to the Prospectus/Consent Solicitation/Offer to Exchange filed with the U.S. Securities and Exchange Commission on January 28, 2026 and declared effective on January 30, 2026 (the “Prospectus/Consent Solicitation/Offer to Exchange”). Continental Stock Transfer &...

With 15+ patents globally and sole AIS-184, EU GSR 2144, and Euro NCAP 2026 certification, drivebuddyAI advances its position as the intelligence layer for mobility BURLINGAME, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN), a global leader in AI at the convergence of insurance and mobility, today announced that drivebuddyAI, its driver safety and in-cabin intelligence platform, has been granted a patent in India for an AI-powered in-vehicle facial recognition system. The system enables real-time driver identification — continuously, while the vehicle is in motion — to strengthen fleet safety, operational accountability, and electronic logging device (ELD) compliance. Driver identity is the foundational input for drivebuddyAI’s entire intelligence stack. Once the system knows who is behind the wheel,...

BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced that its subsidiaries Agape Total Health Care Inc., Franklin Bioscience – Penn LLC, and Franklin Bioscience – SE LLC (collectively, the “Jushi Subsidiaries”) have entered into a Settlement Agreement and Mutual Release with Revelry Supply, Inc. (“Revelry”) effective February 11, 2026, favorably resolving claims asserted in litigation pending in the Court of Common Pleas of Philadelphia County, Pennsylvania. The litigation, styled Agape Total Health Care Inc., et al. v. Golden Hour, LLC, et al., Civil Action No. 250803198, was filed as part of a broader enforcement action initiated by the Jushi Subsidiaries against multiple entities and...

Company strengthens its biometric identity verification and real-time security intelligence with a dedicated hardware solution for access control, debuting ROC Access Face1 at ISC West DENVER, CO, March 25, 2026 (GLOBE NEWSWIRE) — Rank One Computing Corporation d/b/a ROC, (Nasdaq: ROC) (“ROC” or the “Company”), a U.S. leader in multimodal Vision AI, building sovereign biometric, video analytics, and mission intelligence solutions into a unified platform, announces the launch of ROC Access, a new vertical focused on intelligent biometric access control. ROC Access expands the Company’s Vision AI platform into a new operational category of physical access control and combines biometric identity verification with real-time security intelligence. The new product will help organizations make stronger access decisions based on who is...

GUANGZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) — YSX TECH. CO., LTD (NASDAQ: “YSXT”) (the “Company”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced that its core trademark “YSX/YISHENGXIN” has been registered with the United States Patent and Trademark Office under Registration No. 8,116,861. The trademark is registered under Class 42, covering key technology service areas, including website design consulting, webpage design, and software development. The registration is expected to support the Company’s ongoing global expansion initiatives. The Company believes the U.S. trademark registration marks an important step in its broader brand globalization efforts and is expected...

Transformational Achievements Position SecureTech forAccelerated Growth in FY2026 ROSEVILLE, MN, March 25, 2026 (GLOBE NEWSWIRE) — SecureTech Innovations, Inc. (OTCQB: SCTH), a diversified technology holding company advancing artificial intelligence initiatives, industrial 3D printing and manufacturing technologies, and blockchain-based digital infrastructure and assets, today reported its audited financial results for the fiscal year ended December 31, 2025. FY2025 Financial Highlights (All Amounts in USD):Record Revenue: Consolidated FY2025 revenue was $7.7 million, up from nominal prior-year levels following the acquisition of AI UltraProd. Company Records First-Ever Annual Net Profit: $203,298 consolidated net income, $112,777 net income attributable to SecureTech shareholders. Record Gross Profit: Gross profit of $1,902,259...

FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront vehicle or placebo control Quoin remains on track to initiate a Phase 3 study and complete Phase 3 patient recruitment in 2026 and potentially file for NDA approval in 2027 ASHBURN, Va., March 25, 2026 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today provided a clinical and regulatory update from its recent constructive Type C meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate, QRX003, for the treatment of Netherton Syndrome (NS). “We are very...